[Vitamin D and other indicators of calcium-phosphorus metabolism as possible predictors of Parkinson's disease].

Objective: To study a role of vitamin D and other indicators of calcium-phosphorus metabolism as possible predictors of Parkinson's disease (PD).

Material And Methods: The main group consisted of 138 patients with PD, the control group included 79 patients without PD. Serum levels of 25-hydroxyvitamin D (25[OH]D) were determined by chemo-luminescence immunoassay.

[Non-motor conditions in patients with cervical dystonia].

Objective: To study non-motor conditions in people with diabetes in comparison with patients with cervicalgia.

Material And Methods: The study included 170 people. The main group consisted of 120 respondents with cervical dystonia (CD) aged 27 to 82 years.

[Prolonged interferon papillomavirus infection treatment].

Prolonged interferon papillomavirus infection treatment. In patients with recurrent genital HPV caused by human papillomavirus types 6 and 11, the use of genferon suppository according to prolonged scheme (500 000 IU 2 times a day for 10 days and further 500 000 IU 2 times a week for 3 months) in comparison with a short scheme (500 000 IU, 2 times a day for 10 days) is more effective in preventing recurrence of infection due to the normalization, an immune and cytokine status, as well as the elimination of the infectious agent from the affected tissues. Prolongation of the drug use did not cause undesirable side effects.

[The study of the efficacy of Botulinum toxin type A in patients with poststroke upper-limb spasticity ULIS-II: an analysis of Russian patients].

Aim: To assess the efficacy of Botulinum toxin type A (BoNT-A) injections in routine practice.

Material And Methods: An international, post-marketing, multi-center, observational, prospective, longitudinal study included patients ≥18 years with poststroke upper-limb spasticity in whom a decision to inject BoNT-A had already been made, and who had no previous treatment with BoNT-A or BoNT-B within the last 12 weeks. The responder rate was assessed by the patient-centered goal attainment scaling (GAS).